Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With RA
NCT01861782 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2014-03-26
Summary
Prospective open label crossover self controlled study. The study population will randomly be divided into two groups.
The study will take place in Lot Spa Hotel at the Dead Sea in two cycles (one of 16 participants and one of 14 participants) and will be comprised of 3 main stages:
1. Initial exposure to treatment for 14 days excluding Friday and Saturday (each of the two groups will have its own treatment protocol)
2. 12-month washout period
3. Crossover of the two groups and second exposure to treatment for 14 days excluding Friday and Saturday (each of the two groups will have its own treatment protocol).
The population in the study will be composed of patients diagnosed and treated for rheumatoid arthritis at the Soroka University Medical Center who are 18 and above of age.
The patients will be selected by the PI and his team and addressed regarding their willingness to participate in the study.
Conditions
Interventions
- OTHER
-
Dead Sea Solar and Water Treatment
- OTHER
-
Sulfur Pool & Medicinal Mud
Sponsors & Collaborators
-
Soroka University Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2015-06-30
Countries
- Israel
Study Locations
More Related Trials
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study
NCT01382784 ·Status: UNKNOWN
-
Immunoadsorption in Patients With Severe Systemic Sclerosis
NCT01410903 ·Status: TERMINATED ·Phase: NA
-
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis
NCT05692908 ·Status: WITHDRAWN ·Phase: PHASE1
-
Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
NCT03060551 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Fresolimumab In Systemic Sclerosis
NCT01284322 ·Status: COMPLETED ·Phase: PHASE1
-
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
NCT03267277 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
NCT01743612 ·Status: COMPLETED ·Phase: NA
-
A Prospective Cohort Study on Primary Cutaneous Amyloidosis
NCT06998875 ·Status: RECRUITING ·Phase: PHASE4
-
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
NCT01651143 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study With CC-220 in Skin Sarcoidosis
NCT02192489 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
NCT03558854 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
NCT02921971 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
NCT00433485 ·Status: COMPLETED ·Phase: PHASE1
-
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
NCT06438679 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.
NCT03211325 ·Status: COMPLETED ·Phase: NA
-
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
NCT02099136 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of RANKL Inhibition on UV-induced Immunosuppression
NCT01978483 ·Status: COMPLETED ·Phase: PHASE1
-
ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma
NCT05148598 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
NCT03957681 ·Status: COMPLETED ·Phase: PHASE3
-
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
NCT03629002 ·Status: UNKNOWN
-
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
NCT00626665 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
NCT05177380 ·Status: UNKNOWN ·Phase: NA
-
Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers
NCT03406988 ·Status: UNKNOWN ·Phase: NA
-
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
NCT03262922 ·Status: COMPLETED